Astellas Pharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2834 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

Assessing Astellas Pharma (TSE:4503) Valuation After A Sharp Pullback And Strong One Year Return - May 2nd, 2026 8:14 am
Pfizer (PFE) Among Best Medical Stocks Under $30 to Invest In? - Apr 30th, 2026 3:40 pm
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting - Apr 30th, 2026 7:00 am
Are Medical Stocks Lagging Arcellx (ACLX) This Year? - Apr 27th, 2026 7:40 am
Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer - Apr 20th, 2026 5:37 am
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Apr 20th, 2026 4:45 am
A Look At Astellas Pharma’s Valuation After A Strong Year Of Share Price Gains - Apr 10th, 2026 9:09 am
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Apr 10th, 2026 7:40 am
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? - Apr 8th, 2026 6:31 am
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design - Apr 8th, 2026 6:00 am
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? - Mar 25th, 2026 7:40 am
Pfizer aims for wider use of PARP drug in prostate cancer with new data - Mar 19th, 2026 5:37 am
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Mar 6th, 2026 6:21 am
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate - Mar 5th, 2026 10:10 am
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Mar 3rd, 2026 10:48 pm
Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM - Mar 1st, 2026 2:27 am
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus - Feb 28th, 2026 4:12 am
Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial - Feb 27th, 2026 9:39 am
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer - Feb 27th, 2026 8:00 am
Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151 - Feb 25th, 2026 6:00 am